For patients with active, refractory lupus (inadequate response to standard therapies or severe steroid side-effects), the investigational route may justify risk and cost, particularly if access to multiple infusions is arranged. For mild-to-moderate, controlled SLE, conventional treatment remains first-line. Long-term data on safety, durability, and cost-benefit will sharpen decision-making over the next 3–5 years as phase III trials report.
Lupus (systemic lupus erythematosus, SLE) is an autoimmune disease in which the body's immune system mistakenly attacks its own tissues, particularly affecting joints, skin, kidneys, and the nervous system. The condition arises when B cells and T cells lose tolerance to self-antigens, producing damaging antibodies and inflammatory cytokines. Placental mesenchymal stem cells show promise because they release immunomodulatory factors—interleukins, soluble HLA-G, and exosomes containing regulatory microRNAs—that rebalance Th17 and regulatory T-cell populations. Early-stage clinical research (47 registered trials, 6 currently recruiting) suggests this approach may reduce disease activity scores and improve organ function in selected patients, though long-term remission rates remain under investigation.
האם אני מועמד? → · Lupus (SLE): full overview → · עלות זאבת (SLE) → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם